Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial.
Maria Alice Franzoi, Stefan Michels, Sarah Ball et al.
✦ AI-curated · Sources linked
In 30 seconds
The HOPE trial is a multicenter randomized controlled trial assessing a digital self-management support tool for patients with hormone receptor-positive early breast cancer undergoing adjuvant hormonal therapy. The study compares a personalized digital health pathway plus standard care to standard care alone. The primary outcome is the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR45 ET symptoms scale over 12 weeks.
Key findings
- 75% of patients experience ET-related symptoms affecting their quality of life.
- The trial involves 180 patients randomized 1:1 to receive either the digital health pathway or standard care.
- Primary endpoint is the EORTC QLQ-BR45 ET symptoms scale over 12 weeks.
Why it matters
This research addresses a significant gap in managing treatment-related symptoms in breast cancer patients, which can lead to improved adherence to therapy and better overall outcomes. Understanding the effectiveness of digital tools in symptom management is crucial for enhancing patient care.